NBIX Options Traders Turn Bearish as Stock Slides 14%

Options positioning on NBIX has flipped sharply since earnings. The put-call ratio hit 1.00 on August 6 — the highest in three months and a z-score of 3.3 standard deviations above the 20-day mean of 0.85. That is a decisive shift. For most of July, the PCR sat comfortably below 0.88.

The Earnings Hangover Continues

The stock closed at $159.82 on August 6, down 13.8% on the week and 8.2% over the past month. The Q2 print on July 30 triggered a 7.7% single-day drop. A further 10.4% followed on July 31. That two-day unwind erased weeks of pre-earnings buildup — a pattern consistent with a "buy the rumour, sell the news" dynamic in biotech names where the bull case arrives already priced.

The options market is now pricing in continued uncertainty. The PCR move from ~0.85 to 1.00 represents a clear shift toward downside protection. Whether that reflects hedging or outright bearish conviction, the signal is consistent: traders are less comfortable holding the stock unhedged at current levels.

Short Sellers Covered, But Now Paying More to Borrow

Short interest fell 13% over the past month to 5.2% of free float — a meaningful reduction that tracks the post-earnings covering noted in a previous article. That covering has now paused. The cost to borrow jumped 81% over the past week to 0.50%. In absolute terms that remains low. Availability sits at nearly 3,000%, meaning the lending market is extremely loose and shares are easy to borrow. The CTB move is a ripple, not a squeeze signal.

Analysts Still Constructive, But the Gap Has Widened

Ten analysts raised price targets after Q2 results. The mean target now stands at $213. That implies roughly 33% upside from Thursday's close of $159.82 — a gap that has widened sharply as the stock has retreated. Canaccord Genuity moved to $210 from $200. Truist raised to $213. Citigroup sits at $249. Only Morgan Stanley holds an Equal-Weight, with a $196 target.

The Street is not abandoning the thesis. Crenessity's CAH opportunity and Ingrezza's base business remain the core of the bull case. But the widening gap between targets and price reflects a stock that has re-priced lower faster than analysts have revised.

Data Summary

• Price: $159.82 (–13.8% past week)
• PCR: 1.00, z-score +3.3 vs. 20-day mean of 0.85
• SI % FF: 5.2% (–13% past month)
• Cost to borrow: 0.50% (+81% past week), absolute level remains low
• Borrow availability: ~2,971% — lending market wide open
• Consensus mean target: $213.13 (~33% above current price)
• Next earnings: October 30, 2026